USD 2.3 Billion
Erectile Dysfunction Drugs Market Size, Share, Growth Analysis, By Product(Viagra (sildenafil citrate), Cialis (Tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil)), By Route of Administration(Oral Mode of Administration, Injectable Mode of Administration, Other Modes of Administration, and Others.), By Region - Industry Forecast 2024-2031
Report ID:
SQMIG35I2259 |
Region:
Global |
Published Date: October, 2024
Pages:
157
|Tables:
65
|Figures:
75
Erectile Dysfunction Drugs Market Insights
Global Erectile Dysfunction Drugs Market size was valued at USD 2.4 billion in 2022 and is poised to grow from USD 2.62 billion in 2023 to USD 5.3 billion by 2031, growing at a CAGR of 9.20% during the forecast period (2024-2031).
The increasing prevalence of sexual dysfunction (ED) is one of the major drivers for erectile dysfunction drugs market growth during the forecast period. ED is a condition in which men lose control due to physical and mental health issues, including diabetes, high cholesterol, smoking, stress and mental illness. According to a WHO report, approximately 15% of men are affected by ED each year, which is projected to reach 320 million by 2025. ED is closely linked to both physical and psychological health. Major risk factors include diabetes mellitus, heart disease, hypertension, and increased HDL levels. In addition, medications for hypertension, diabetes, depression, and cardiovascular disease can contribute to erectile difficulties.
ED is the most common condition in older men. Decreased natural testosterone levels, blood pressure, and other age-related physiological changes contribute to the increased risk of ED in older men. This disease has a significant impact on a patient’s quality of life and healthcare resources. Older people are more likely to have chronic conditions such as diabetes, heart disease and hypertension, which are major risk factors for ED and therefore the increasing number of older people is a major reason for breakdown of ED in men in the coming years. Technological advancement in drug delivery, the high burden of diseases and improved healthcare are some of the factors driving the growth of the market. Furthermore, increasing demand for potent pharmaceutical formulations to combat the increasing prevalence of ED is one of the major factors driving the growth in the consumption of ED drugs. The market is expected to grow by increasing R&D investments in new drugs for ED patients.
Market snapshot - 2024-2031
Global Market Size
Largest Segment
Oral Mode of Administration
Fastest Growth
Injectable Mode of Administration
Growth Rate
8.5% CAGR
Global Erectile Dysfunction Drugs Market ($ Bn)
Country Share for North America Region (%)
To get more reports on the above market click here to Buy The Report
Erectile Dysfunction Drugs Market Segmental Analysis
Global Erectile Dysfunction Drugs Market is segmented by Type, Route of Administration, and region. Based on Type, the market is segmented into Viagra (sildenafil citrate), Cialis (Tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), and Other Drugs. Based on Route of Administration, the market is segmented into Oral Mode of Administration, Injectable Mode of Administration, and Other Modes of Administration. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.
Analysis by Type
The viagra (sildenafil citrate) segment dominated the market and accounted for the largest revenue share of 57.3% in 2023. Viagra (sildenafil citrate) was the first phosphodiesterase 5 (PDE5) inhibitor drug approved by Pfizer Inc as they are not used for erectile dysfunction (ED). The patent for the branded version of Viagra expired in 2020, and therefore, to fill the demand gap in the market, Pfizer Inc. launched a generic version of Viagra at half the retail price-USD 65. Some of the leading companies offering generics produce versions of Viagra with drugs varieties under Aurobindo Pharma USA, Lupine, Sunshine Lake Pharma, and Torrent Pharmaceuticals. In addition, there are strategic initiatives led by local players to expand their business activities such as joint research, partnerships, alliances etc. Moreover, the availability of supportive reimbursement schemes for Viagra positively influences market development.
The cialis (tadalafil) segment plays a pivotal role in the erectile dysfunction drugs market as one of the most widely recognized and utilized treatments. The segment is expected to emerge as the most profitable segment and is likely to grow at a CAGR of 8.9% during the forecast period. Other medications such as Mirodenafil (Mvix), Helleva (lodenafil Carbonate), MAXON Forte, and Maxon Active are also used to treat adult patients with ED. Helleva was developed by Cristalia and is prescribed to men suffering from ED. Initially, it was approved in Brazil. MAXON Forte and Maxon Active are OTC products of Adamed indicated for the treatment of adult patients with ED. These are composed of 25 mg sildenafil citrate and cost around USD 311.75 for ten tablets. Moreover, the approval of products for OTC sales is anticipated to fuel market growth.
Analysis by Route of Administration
The oral mode of administration segment held the largest market share of 84.03% in 2024. Oral ED drugs, including phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil, tadalafil, vardenafil, for the management of the disease effective proven clinical ease of administration in some formulations. Besides patient adherence to top and market demand coupled with rapid onset and extended duration of surgery. Continuous development of new medicines such as sublingual medicines and chewable medicines expands this segment. However, market players must address the potential for side effects and drug interactions to maintain consumer confidence and ensure continued growth in the segment.
The injectable mode of administration segment is estimated to grow at a CAGR of 10.4% during the forecast period. Other delivery methods include topical and intravenous solutions. The rise of new intrathecal drugs and growing awareness are expected to fuel the market growth during the forecast period. Topical drugs for the treatment of ED include alprostadil cream (Vitaros), nitroglycerin-based oils and Iroxan. In June 2023, the U.S. FDA granted permission to Future Medical for marketing and OTC selling of Eroxon medicine indicated to treat patients with ED in the U.S. Eroxon is a topical gel that offers an erection within 10 minutes compared to other drugs.
Global Erectile Dysfunction Drugs Market By Route of Administration (%)
To get detailed analysis on other segments, Request For Free Sample Report
Erectile Dysfunction Drugs Market Regional Insights
As per erectile dysfunction drugs market outlook, North America dominated and accounted for 50.55% of the revenue share in 2023. Moreover, the advancement in medical technology has led to therapeutics effective and convenient for ED. This has encouraged more individuals to seek treatment and expanded the market for ED drugs. Sedentary lifestyle, stress, unhealthy eating habits, and other lifestyle factors contributed to the prevalence of ED diseases greater burden, improved health care and innovations. In addition, advances in medical science have led to the development of effective and convenient treatment options for ED. This has encouraged more individuals to seek treatment and expanded the market. Furthermore, increasing demand for ED and personalized nutrition is also contributing to the growth of the market.
As per erectile dysfunction drugs market analysis, the Asia-Pacific region in the erectile dysfunction drugs market is expected to grow rapidly during the forecast period owing to the increasing prevalence of ED in Asian countries. Moreover, rapidly growing elderly population in countries such as China and Japan are expected to fuel the market growth. The erectile dysfunction drugs market in China is anticipated to grow at an exciting growth rate during the forecast period. The demand for erectile dysfunction drugs is increasing in China due to factors such as aging population, lifestyle changes and chronic health conditions.
Global Erectile Dysfunction Drugs Market By Geography
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Erectile Dysfunction Drugs Market Dynamics
Erectile Dysfunction Drugs Market Drivers
Increasing Prevalence of Erectile Dysfunction
-
The increasing prevalence of erectile dysfunction (ED), especially among the elderly population, is one of the major drivers of the market. Lifestyle factors such as poor nutrition, lack of exercise and increased stress have further contributed to an increasing number of younger individuals experiencing ED. Many individuals under its influence seek medical help, leading to the search for erectile dysfunction and female sexual dysfunction.
Increased Awareness and Social Acceptance
-
Public awareness campaigns and changing public perceptions of EDs play an important role in the growth of the market. Pharmaceutical companies have also launched targeted marketing campaigns to standardize ED drugs, making them accessible to wider populations. Besides, telemedicine availability has made it easier for patients to discreetly contact healthcare providers and obtain prescriptions, further fueling market growth.
Erectile Dysfunction Drugs Market Restraints
Side Effects and Safety Concerns
-
The market faces challenges due to potential adverse effects associated with aphrodisiacs, including headaches, dizziness, vision changes and cardiovascular risks. These concerns can deter individuals from exploring drug solutions, especially in elderly patients or those with pre-existing health conditions. Negative perception towards long-term ED drugs also hampered the market growth.
Availability of Alternative Therapies
-
The increasing availability of non-pharmaceutical alternatives such as penile injections, shock waves, and herbal supplements is a major restriction in the market. Many patients prefer these alternatives due to concerns about drug dependence and side effects. In addition, advances in regenerative medicine, including stem cell therapy and platelet-rich platelet (PRP) therapy, have offered new solutions to conventional ED drugs.
Request Free Customization of this report to help us to meet your business objectives.
Erectile Dysfunction Drugs Market Competitive Landscape
The competitive landscape of the global erectile dysfunction drugs market is characterized by intense competition and a range of players striving to capture a significant market share. The market is highly dynamic, with multiple pharmaceutical companies and manufacturers vying to provide effective treatment options for erectile dysfunction. These players focus on research and development activities to develop innovative drugs and enhance existing formulations. Strategic alliances, collaborations, and partnerships with healthcare providers, research institutions, and distribution networks are common strategies employed to gain a competitive edge. Additionally, marketing initiatives, brand building, and extensive product promotion are crucial for market penetration and creating awareness among target consumers. The competitive landscape is further influenced by factors such as patent protections, regulatory approvals, pricing strategies, and the ability to address safety concerns associated with these drugs. The presence of generic alternatives also impacts competition and market dynamics. Overall, the global erectile dysfunction drugs market presents a competitive environment driven by innovation, strategic partnerships, and effective marketing strategies.
Top Player’s Company Profile
- Merck & Co., Inc. (US)
- Bausch Health Companies Inc. (Canada)
- Hims, Inc. (US)
- Sildenafil Therapeutics LLC (US)
- Eli Lilly and Company (US)
- MediSprout (US)
- NantKwest, Inc. (US)
- Apexigen, Inc. (US)
- NantWorks LLC (US)
- Sorrento Therapeutics, Inc. (US)
Recent Developments
- In February 2024, Hims & Hers partnered with Hartford Healthcare (HHC) to increase personalized health care services. The partnership allowed for a seamless transition from Hims & Hers platform for complex medical needs to HHC’s extensive network.
- In May 2024, Petros Pharmaceuticals and 23andMe partnered with Lemonaid Health, a subsidiary of 23andMe, to offer all strengths of STENDRA (avanafil) for ED on Lemonaid's telehealth platform. The partnership aims to increase access to STENDRA throughout the country, has increased brand awareness.
- In September 2021, iX Biopharma, through its wholly owned subsidiary, entered into an agreement with CRPCG to license, supply and distribute Wafesil, a sublingual sildenafil wafer for the treatment of male erectile dysfunction in China.
Erectile Dysfunction Drugs Key Market Trends
- Emergence of Over the Counter (OTC) Drugs: A major erectile dysfunction drugs market trend in the market is the increasing availability of over the counter (OTC) drugs for erectile dysfunction. Companies are investing in making popular ED drugs available without a prescription, expanding their reach to a broader consumer base. This trend is particularly evident in areas with progressive legal systems.
- Focus on New Drug Development: The market is witnessing R&D activities aimed at developing next generation ED drugs with improved efficacy and reduced side effects. Pharmaceutical companies are also exploring the use of nitric oxide enhancers, gene therapy, and targeted delivery systems to provide better solutions for patients who are unresponsive to traditional treatments. This development is expected to significantly change the market landscape over the next decade.
Erectile Dysfunction Drugs Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
According to SkyQuest analysis, the market for erectile dysfunction drugs is driven by the growth of EDs and increasing awareness, driven by changing public attitudes and convenience of telemedicine. But challenges such as safety concerns and competition from other treatments may inhibit progression. Key trends such as the emergence of OTC ED drugs and innovations in pharmaceutical manufacturing are reshaping the market, providing important opportunities for expansion. As awareness and accessibility continues to improve, the market is set to witness steady growth, driven by the demand for safe, effective and easily accessible treatments.
| Report Metric | Details |
|---|---|
| Market size value in 2022 | USD 2.4 billion |
| Market size value in 2031 | USD 5.3 billion |
| Growth Rate | 9.20% |
| Base year | 2023 |
| Forecast period | 2024-2031 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Erectile Dysfunction Drugs Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Erectile Dysfunction Drugs Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Erectile Dysfunction Drugs Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Erectile Dysfunction Drugs Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Erectile Dysfunction Drugs Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Erectile Dysfunction Drugs Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
